Acute-on-chronic liver failure: The heart and systemic hemodynamics

Current Opinion in Critical Care

Volumn 17, Issue 2, 2011, Pages 190-194

  Liu, Hongqun ^a   Lee, Samuel S ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

acute on chronic liver failure; cirrhotic cardiomyopathy; hyperdynamic circulation; molecular adsorbent recirculating system

Indexed keywords

ALDOSTERONE; ANTIBIOTIC AGENT; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCORTISONE; INTERLEUKIN 6; LACTULOSE; NITRIC OXIDE; NORADRENALIN; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ACUTE ON CHRONIC LIVER FAILURE; ADRENAL INSUFFICIENCY; ALBUMIN DIALYSIS; ASCITES; BACTERIAL PERITONITIS; BRAIN DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CIRCULATION; CIRRHOTIC CARDIOMYOPATHY; CORTICOTROPIN TEST; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ESOPHAGUS VARICES BLEEDING; HEART HEMODYNAMICS; HEART OUTPUT; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERDYNAMIC CIRCULATION; HYPOVOLEMIA; INFECTION; INFLAMMATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MORTALITY; PROTEIN BLOOD LEVEL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME; VASODILATATION;

BIOLOGICAL MARKERS; CARDIOMYOPATHIES; END STAGE LIVER DISEASE; HEMODYNAMICS; HUMANS; INFLAMMATION; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; SHOCK;

EID: 79953090390     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328344b397     Document Type: Review

References (39)

1. Kumar A, Das K, Sharma P, et al. Hemodynamic studies in acute-on-chronic liver failure. Dig Dis Sci 2009;54:869-878. Demonstrated the similarity of systemic hemodynamics in patients with ACLF and those in decompensated cirrhotics.
2. Breitman DR, Lee SS. Blunted responsiveness of the neuronal activation marker Fos in brainstem cardiovascular nuclei of cirrhotic rats. Hepatology 1997;26:1380-1385. (Pubitemid 27519999)
3. Song D, Liu H, Sharkey KA, Lee SS. Hyperdynamic circulation in portalhypertensive rats is dependent on central c-fos gene expression. Hepatology 2002;35:159-166. (Pubitemid 34032556)
4. Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut 2008;57:966-973. (Pubitemid 351919531)
5. Lee SS, Baik SK. Clinical consequences of cirrhosis: cardiovascular. In: Boyer TD, Wright T, Manns MP, editors. Zakim and Boyer's hepatology. Philadelphia: Saunders; 2006. pp. 453-475.
6. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-2375.
7. Jalan R, Olde Damink SW, Ter Steege JC, et al. Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. J Hepatol 2011;54:265-271. Circulatory failure in ACLF is iNOS dependent.
8. Aravinthan A, Al-Naeeb Y, Richardson P. Relative adrenal insufficiency in a patient with liver disease. Eur J Gastroenterol Hepatol 2009;21:381-383. Adrenal insufficiency in patients with ACLF causes the de-sensitivity of the vasculature to vasoconstrictors.
9. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006;44:1288-1295. (Pubitemid 44748379)
10. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of 'low-dose'hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-520.
11. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990;87:10043-10047. (Pubitemid 120016581)
12. Aravinthan A, Al-Naeeb Y, Richardson P. Relative adrenal insufficiency in a patient with liver disease. Eur J Gastroenterol Hepatol 2009;21:471-473.
13. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portalhypertensive rats. Gastroenterology 1995;108:761-767.
14. Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006;10: R169.
15. Novelli G, Annesini MC, Morabito V, et al. Cytokine level modifications: molecular adsorbent recirculating system versus standard medical therapy. Transplant Proc 2009;41:1243-1248. MARS liver support device reverts levels of cytokines, such as IL-6, IL-1, IL-10, TNF-a toward normal.
16. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-491. (Pubitemid 34110432)
17. Helmy A, Newby DE, Jalan R, et al. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003;38:44-50. (Pubitemid 36078523)
18. La Villa G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27. (Pubitemid 32591478)
19. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-2018. (Pubitemid 19187609)
20. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999;43:532-541. (Pubitemid 29369252)
21. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074-G1081. (Pubitemid 35192843)
22. Xu L, Carter EP, Ohara M, et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol Renal Physiol 2000;279: F1110-F1115. (Pubitemid 32001633)
23. Biecker E, Neef M, Sagesser H, et al. Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock-out mice and is elevated in murine and human cirrhosis. Liver Int 2004;24:345-353. (Pubitemid 39162074)
24. Li Y, Liu H, Gaskari SA, et al. Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol 2008;295: G252-G259.
25. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10: R108.
26. Arroyo V, Jimenez W. Complications of cirrhosis. II: Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32:157-170. (Pubitemid 30123632)
27. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487. (Pubitemid 18054789)
28. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52. (Pubitemid 32102551)
29. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218. (Pubitemid 37314829)
30. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003;38:1089-1091. (Pubitemid 37314816)
31. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008;28:59-69. (Pubitemid 351326533)
32. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006;12:837-842.
33. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006;3:329-337. (Pubitemid 43842249)
34. Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415-421.
35. Catalina MV, Barrio J, Anaya F, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23(Suppl 3):39-43. (Pubitemid 37264917)
36. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005;43:142-148. (Pubitemid 40805285)
37. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:1182-1187. (Pubitemid 36877433)
38. Aller R, de Luis DA, Moreira V, et al. The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement. J Endocrinol Invest 2001;24:503-509. (Pubitemid 32691163)
39. Siniscalchi A, Dante A, Spedicato S, et al. Hyperdynamic circulation in acute liver failure: reperfusion syndrome and outcome following liver transplantation. Transplant Proc 2010;42:1197-1199.